Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Hal
Go back to Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Hal| (NASDAQ: MCRB) | Delayed: 4.00 -0.1 (2.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.10 | 52 Week High | $44.51 | |||
| Open | $4.11 | 52 Week Low | $8.05 | |||
| Day High | $4.27 | P/E | N/A | |||
| Day Low | $4.00 | EPS | $0.00 | |||
| Volume | 95,100 | |||||
